CLARITY PHARMACEUTICALS LIMITED (CU6)
Share Price Analysis and Chart

Enter the company code or Name for stock analysis:

CU6

CU6 - CLARITY PHARMACEUTICALS LIMITED

FNArena Sector : Medical Equipment & Devices
Year End: June
GICS Industry Group : Pharmaceuticals, Biotechnology & Life Sciences
Debt/EBITDA: -0
Index: ASX200 | ASX300 | ALL-ORDS

LAST PRICE CHANGE +/- CHANGE % VOLUME

$2.78

21 Mar
2025

-0.050

OPEN

$2.84

-1.77%

HIGH

$2.93

1,677,254

LOW

$2.77

TARGET
$6.95

+1.75 change from previous day

 150.0% upside
OTHER COMPANIES IN THE SAME SECTOR
4DX . AT1 . AYA . BB1 . BRN . CAT . CBL . CGS . CMP . COH . CSX . CVB . CYC . EBR . EMV . EYE . FPH . IDX . IME . IMR . IPD . LDX . MX1 . NAN . ONE . PCK . PEB . PGC . PME . RMD . SOM . TRJ . UBI .
FNARENA'S MARKET CONSENSUS FORECASTS
CU6: 1
Title FY23
Actual		 FY24
Actual		 FY25
Forecast		 FY26
Forecast
EPS (cps) xxx - 15.5 - 17.7 xxx
DPS (cps) xxx 0.0 0.0 xxx
EPS Growth xxx N/A N/A xxx
DPS Growth xxx N/A N/A xxx
PE Ratio xxx N/A N/A xxx
Dividend Yield xxx N/A 0.0% xxx
Div Pay Ratio(%) xxx N/A N/A xxx

Dividend yield today if purchased 3 years ago: 0.00%

DIVIDEND YIELD CALCULATOR

Dividend Yield Today On Last Actual Payout :

 0.00

Estimated Dividend Growth
(Average Of Past Three Years)

  %

Amount Invested

 $ 

Tell Me The Dividend After This Many Years
Past performance is no guarantee for the future. Investors should take into account that heavy swings in share price or exceptional circumstances (a la 2009) can have a significant impact on short term calculations and averages
HISTORICAL DATA ARE ALL IN AUD
Copyright © 2025 FactSet UK Limited. All rights reserved
Title 201920202021202220232024
EPS Basic xxxxxxxxxxxxxxx-15.5
DPS All xxxxxxxxxxxxxxx0.0
Sales/Revenue xxxxxxxxxxxxxxx0.0 M
Book Value Per Share xxxxxxxxxxxxxxx46.9
Net Operating Cash Flow xxxxxxxxxxxxxxx-43.2 M
Net Profit Margin xxxxxxxxxxxxxxx-

EPS Basic

DPS All

Sales/Revenue

Book Value Per Share

Net Operating Cash Flow

Net Profit Margin

Title 201920202021202220232024
Return on Capital Employed xxxxxxxxxxxxxxx-39.29 %
Return on Invested Capital xxxxxxxxxxxxxxx-39.29 %
Return on Assets xxxxxxxxxxxxxxx-36.56 %
Return on Equity xxxxxxxxxxxxxxx-39.29 %
Return on Total Capital xxxxxxxxxxxxxxx-52.26 %
Free Cash Flow ex dividends xxxxxxxxxxxxxxx-43.7 M

Return on Capital Employed

Return on Invested Capital

Return on Assets

Return on Equity

Return on Total Capital

Free Cash Flow ex dividends

Title 201920202021202220232024
Short-Term Debt xxxxxxxxxxxxxxx0 M
Long Term Debt xxxxxxxxxxxxxxx0 M
Total Debt xxxxxxxxxxxxxxx0 M
Goodwill - Gross xxxxxxxxxxxxxxx-
Cash & Equivalents - Generic xxxxxxxxxxxxxxx137 M
Price To Book Value xxxxxxxxxxxxxxx11.55

Short-Term Debt

Long Term Debt

Total Debt

Goodwill - Gross

Cash & Equivalents - Generic

Price To Book Value

Title 201920202021202220232024
Capex xxxxxxxxxxxxxxx0.5 M
Capex % of Sales xxxxxxxxxxxxxxx-
Cost of Goods Sold xxxxxxxxxxxxxxx0 M
Selling, General & Admin. Exp & Other xxxxxxxxxxxxxxx56 M
Research & Development xxxxxxxxxxxxxxx46 M
Investments - Total xxxxxxxxxxxxxxx0 M

Capex

Capex % of Sales

Cost of Goods Sold

Selling, General & Admin. Exp & Other

Research & Development

Investments - Total

EXPERT VIEWS
Display All Commentary

Sentiment Indicator

1.0

No. Of Recommendations

1
BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Ord Minnett

xx/xx/xxxx

-1

xxxxxxxx xxxxxxxx xxxx x xxx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Bell Potter

14/03/2025

1

Speculative Buy

$5.20

87.05%

Bell Potter notes Clarity Pharmaceuticals is advancing its Secure trial, targeting pre-chemotherapy and pre-hormone therapy patients with metastatic castration-resistant prostate cancer.

The broker highlights strong clinical data, with 62% of pre-chemotherapy patients achieving prostate-specific antigen (PSA) reductions of at least -50%, outperforming industry benchmarks.

Management expects expansion cohort data in late 2025 or early 2026, which could support future M&A interest.

House rules at Bell Potter determine valuations on speculative stocks are limited to 100% upside from market price, hence the valuation for Clarity Pharmaceuticals is reduced to $5.20 from $10.00. Speculative Buy rating retained.

FORECAST
Bell Potter forecasts a full year FY25 dividend of 0.00 cents and EPS of minus -17.70 cents.
Bell Potter forecasts a full year FY26 dividend of 0.00 cents and EPS of minus -20.40 cents.
Access Stockbroker Research History >
EXTRA COVERAGE
Display All Commentary

No. Of Recommendations

2

Please note: unlike Broker Call Report, BC Extra is not updated daily. The info you see might not be the latest. FNArena does its best to update ASAP.

BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Wilsons

xx/xx/xxxx

1

xxxxxxxxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Canaccord Genuity

10/03/2025

1

Buy

$8.06

189.93%

First half results from Clarity Pharmaceuticals were largely in line although Canaccord Genuity notes the actual cash position was $10m above forecast.

The major news centred on the neuroblastoma trial assessing the utility of the company's therapy. Despite a setback with a grade 5 dose-limiting toxicity (death) the safety review committee has recommended the trial continue, amid a lack of treatment options for these patients.

The broker does not make any changes to assumptions regarding the program and remains cautious about extrapolating results between the company's programs given different indications and patient groups.

The broker also notes the phase two SECuRE trial update included data from cohort 4 patients who received high doses of 12 GBq, and it showed efficacy continues to be strong.

The Buy rating and $8.06 target are unchanged.

FORECAST
Canaccord Genuity forecasts a full year FY25 dividend of 0.00 cents and EPS of minus -17.20 cents.
Canaccord Genuity forecasts a full year FY26 dividend of 0.00 cents and EPS of minus -28.70 cents.
Access Extra Coverage Research History >

CU6 STOCK CHART

FNArena News on CU6

1
Australian Broker Call *Extra* Edition – Mar 10, 2025

Mar 10 2025 - Daily Market Reports
2
In Brief: Top Picks In Financials, Retail & Healthcare

Mar 07 2025 - Weekly Reports
3
Rudi’s View: To Sell Or Not To Sell

Mar 06 2025 - Rudi's View
4
Next Week At A Glance – 24-28 Feb 2025

Feb 21 2025 - Weekly Reports
5
Rudi’s View: Best Ideas & Conviction Calls

Feb 20 2025 - Rudi's View

Latest Medical Equipment & Devices News

1
Trend Remains Up For Catapult International

Feb 18 2025 - Technicals
2
ESG Focus: Top ASX Companies, Superbugs & Hydrogen

Feb 07 2025 - ESG Focus
3
ResMed Shakes Off GLP-1 Scare

Feb 04 2025 - Australia
4
ResMed: Another Positive Quarterly Surprise?

Jan 30 2025 - Australia
5
The Trend Remains Pro Medicus’ Friend

Jan 16 2025 - Technicals
6
Diagnostic Imaging Radiates Opportunity

Dec 18 2024 - Small Caps
7
ResMed’s Bounce-Back Complete

Oct 29 2024 - Australia
8
Dr Boreham’s Crucible: Pro Medicus

Sep 04 2024 - Australia
9
Pro Medicus: Don’t Stop Me Now

Aug 20 2024 - Technicals
10
Dr Boreham’s Crucible: Blinklab

May 20 2024 - Small Caps